Cat. No.: DAB-0011942
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Host Species | Mouse |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with 3-methylcholanthrene-induced rat liver microsomal fractions. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CYP1A2 |
| UniProt No. | P05177 |
| Gene ID | 1544 |
| Gene Description | Cytochrome P450 is a family of enzymes that contain a heme group. These enzymes, when reduced and bound by carbon monoxide, maximally absorb light of 450 nm. Type I cytochrome P450s are found in mitochondria and function in the biosynthesis of essential molecules. Type II cytochrome P450s are found in endoplasmic reticulum. Some type II cytochrome P450s play a role in the biosynthesis of essential molecules whereas others metabolize xenobiotics. Research studies show that cytochrome P450s form various heteromeric complexes with other members of the P450 family influencing their catalytic activities. CYP1A2 is in the endoplasmic reticulum of hepatocytes and responsible for the breakdown of a variety of xenobiotic substances and bioactivation of carcinogens. CYP1 enzymes, including CYP1A2, have been implicated in smoking-related osteoporosis. A meta-analysis shows that a particular polymorphism in CYP1A2 is potentially linked to increased cancer risk. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
